– May 1, 2012
May 1, 2012
View Issues
Cetuximab Adds No Benefit to Adjuvant Chemotherapy in Stage III Colon Cancer
This randomized Phase 3 clinical trial found that adding cetuximab to standard mFOLFOX6 adjuvant chemotherapy did not improve either overall survival or disease-free survival in patients with resected stage III colon cancer, including those with wild-type KRAS tumors.Occult Axillary Node Metastasis in Early-stage Breast Cancer: Important or Not?
In a retrospective review of 267 patients evaluated at M.D. Anderson Cancer Center with apparent early-stage, node-negative breast cancer, 15% were found to harbor "occult" metastases upon more intensive scrutiny of the axillary node specimens. In this series, long-term follow-up indicates that such discovery was not associated with a greater frequency of recurrence or poorer survival.Randomized, Double-Blind, Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System
In a small, single-institutional, prospective, randomized, placebo-controlled trial, 14 eligible patients (median age 47 years) with clinical and radiographic evidence of radiation necrosis secondary to prior head-and-neck or CNS irradiation were randomized to receive intravenous saline of bevacizumab at 3-week intervals. Patients were followed with serial MRI scans, neurologic examinations, and formal neuropsychological examinations.Solitary Colorectal Pulmonary Metastasis
A 61-year-old small business owner was seen in consultation for advice regarding management of a newly discovered pulmonary mass. Seven years previously, he had a 3.5 cm moderately differentiated adenocarcinoma of the sigmoid colon resected along with four regional nodes, all of which were negative for metastatic involvement.Clinical Briefs in Primary Care Supplement
Pharmacology Watch
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.